Sakuma Mei, Mimura Kosaku, Nakajima Shotaro, Kaneta Akinao, Kikuchi Tomohiro, Nirei Azuma, Tada Takeshi, Hanayama Hiroyuki, Okayama Hirokazu, Sakamoto Wataru, Saito Motonobu, Momma Tomoyuki, Saze Zenichiro, Kono Koji
Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Cancers (Basel). 2023 Jul 16;15(14):3641. doi: 10.3390/cancers15143641.
In order to develop a biomarker predicting the efficacy of treatments for patients with esophageal squamous cell carcinoma (ESCC), we evaluated the subpopulation of T cells in ESCC patients treated with chemotherapy (CT), chemoradiotherapy (CRT), and nivolumab therapy (NT). Fifty-five ESCC patients were enrolled in this study, and peripheral blood samples were collected before and after CT or CRT and during NT. Frequencies of memory, differentiated, and exhausted T cells were evaluated using flow cytometry among cStages, treatment strategies, pathological responses of CT/CRT, and during NT. The frequencies of PD-1 or TIM-3CD4 T cells were significantly higher in patients with cStage IV. PD-1CD4 and TIM-3CD8 T-cell populations were significantly higher in patients treated with CRT but were not associated with treatment response. The frequencies of both CD4 and CD8 CD45RACD27CD127 central memory T cells (T) were significantly decreased during the course of NT in the progressive disease group. Taken together, the alteration in frequency of CD45RACD27CD127 T during NT may be a biomarker to predict its therapeutic response in ESCC patients.
为了开发一种能够预测食管鳞状细胞癌（ESCC）患者治疗疗效的生物标志物，我们评估了接受化疗（CT）、放化疗（CRT）和纳武单抗治疗（NT）的ESCC患者的T细胞亚群。55例ESCC患者纳入本研究，在CT或CRT前后以及NT期间采集外周血样本。在不同临床分期、治疗策略、CT/CRT的病理反应以及NT期间，采用流式细胞术评估记忆性、分化性和耗竭性T细胞的频率。cIV期患者中PD-1或TIM-3⁺CD4⁺ T细胞的频率显著更高。接受CRT治疗的患者中，PD-1⁺CD4⁺和TIM-3⁺CD8⁺ T细胞群体显著更高，但与治疗反应无关。在疾病进展组的NT过程中，CD4⁺和CD8⁺ CD45RA⁺CD27⁺CD127⁺ 中央记忆T细胞（Tcm）的频率均显著降低。综上所述，NT期间CD45RA⁺CD27⁺CD127⁺ Tcm频率的改变可能是预测ESCC患者治疗反应的生物标志物。
